ACE2 and hematocrit: One mechanism is that HT patients are often treated with ACE inhibitors (ACEIs) or angiotensin II type‐I receptor blockers (ARBs), which have been previously suggested to increase ACE2 expression (Ferrario et al, 2005; Liang et al, 2015; Vuille‐dit‐Bille et al, 2015; Li et al, 2017).